Latest news with #LigaChemBiosciences
Yahoo
4 days ago
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
4 days ago
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
4 days ago
- Business
- Yahoo
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers. A scientist in a lab researching the biology of a cancer cell. The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy. According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session. NXTC closed nearly 6% higher on May 29. While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
3 Asian Stocks Estimated To Be Trading Below Intrinsic Value In May 2025
As global markets experience volatility amid renewed tariff threats and fluctuating economic indicators, Asian stock markets are also navigating these challenging conditions. In such an environment, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.27 CN¥28.25 49.5% Livero (TSE:9245) ¥1694.00 ¥3383.28 49.9% Range Intelligent Computing Technology Group (SZSE:300442) CN¥43.44 CN¥85.01 48.9% Devsisters (KOSDAQ:A194480) ₩38100.00 ₩76151.09 50% Zhuhai CosMX Battery (SHSE:688772) CN¥13.46 CN¥26.77 49.7% Kolmar Korea (KOSE:A161890) ₩84600.00 ₩168491.07 49.8% Kanto Denka Kogyo (TSE:4047) ¥832.00 ¥1644.44 49.4% KG Mobilians (KOSDAQ:A046440) ₩4255.00 ₩8288.55 48.7% SpiderPlus (TSE:4192) ¥460.00 ¥919.15 50% Cosmax (KOSE:A192820) ₩209500.00 ₩407469.70 48.6% Click here to see the full list of 298 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: LigaChem Biosciences Inc. is a clinical stage biopharmaceutical company focused on discovering and developing medicines for unmet medical needs, with a market cap of ₩4 trillion. Operations: The company generates revenue from two main segments: Pharmaceutical Business, contributing ₩20.54 billion, and New Drug Research and Development, accounting for ₩105.36 billion. Estimated Discount To Fair Value: 33.3% LigaChem Biosciences is trading at ₩110,400, considerably below its estimated fair value of ₩165,629.14. Despite recent negative sales figures, the company turned profitable with a net income of KRW 7.8 billion in 2024 and forecasts significant earnings growth of 58.9% annually over three years. The strategic alliance with WuXi XDC enhances ADC development capabilities, potentially boosting cash flows further as LigaChem capitalizes on this partnership for innovative therapies. Insights from our recent growth report point to a promising forecast for LigaChem Biosciences' business outlook. Unlock comprehensive insights into our analysis of LigaChem Biosciences stock in this financial health report. Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market cap of approximately HK$31.70 billion. Operations: RemeGen's revenue is primarily derived from its biopharmaceutical research, service, production, and sales segment, totaling CN¥1.91 billion. Estimated Discount To Fair Value: 34.1% RemeGen's stock, trading at HK$51.2, is significantly undervalued compared to its estimated fair value of HK$77.67. The company's revenue growth forecast of 23.2% annually outpaces the Hong Kong market average and it is expected to become profitable within three years. Recent advancements include successful clinical trials for disitamab vedotin, enhancing its therapeutic portfolio and potential cash flows despite a volatile share price and ongoing net losses reported in Q1 2025 earnings results. Our earnings growth report unveils the potential for significant increases in RemeGen's future results. Click here to discover the nuances of RemeGen with our detailed financial health report. Overview: Chugin Financial Group Inc., with a market cap of ¥307.82 billion, operates through its subsidiary The Chugoku Bank, Limited to offer a range of financial services to both corporate and individual clients in Japan. Operations: The company's revenue segments include ¥11.73 billion from the Banking segment, ¥14.54 million from the Lease segment, and ¥3.97 million from the Securities Industry. Estimated Discount To Fair Value: 19.7% Chugin Financial Group, Inc. is trading at ¥1,720.5, below its estimated fair value of ¥2,141.51. Forecasted revenue growth of 33.1% annually surpasses Japan's market average significantly, while earnings are expected to grow at 14.3% per year. The company announced a share buyback program and increased dividends for fiscal 2026 to enhance shareholder returns despite recent share price volatility and a low return on equity forecast of 7%. In light of our recent growth report, it seems possible that Chugin Financial GroupInc's financial performance will exceed current levels. Click here and access our complete balance sheet health report to understand the dynamics of Chugin Financial GroupInc. Navigate through the entire inventory of 298 Undervalued Asian Stocks Based On Cash Flows here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A141080 SEHK:9995 and TSE:5832. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Business Upturn
22-04-2025
- Business
- Business Upturn
1STBIO and LigaChemBio Announce Strategic R&D and Licensing Option Agreement
Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeutics Focus on breakthrough ADC payloads and immuno-oncology candidates with out-licensing potential YONGIN, South Korea, April 22, 2025 — 1ST Biotherapeutics, Inc. ('1STBIO') and LigaChem Biosciences (KOSDAQ: 141080KS, 'LigaChemBio') announced that they have entered into a strategic partnership and licensing option agreement to co-develop novel payloads for antibody-drug conjugates (ADCs) as well as small molecule immuno-oncology therapies. Under the terms of the agreement, the two companies will collaborate to identify and develop 2–4 novel drug candidates over the next three years, including next-generation ADC payloads and small molecule oncology assets. LigaChemBio will provide initial funding for joint R&D activities and retain exclusive licensing options for the resulting candidates. Upon exercising the option, LigaChemBio will have the right to out-license assets to third parties and share revenues with 1STBIO. Further financial details were not disclosed. The agreement builds on an ongoing joint research project that began in December 2024. Recognizing a strong fit and potential synergies between the teams, LigaChem Bio opted to expand the alliance. The partnership is expected to overcome limitations of current ADC payloads and unlock first-in-class or best-in-class oncology programs. '1STBIO's cutting-edge R&D capabilities are at the core of this collaboration,' said Jamie Jae Eun Kim, CEO of 1ST Biotherapeutics. 'By combining our strengths, we aim to not only advance ADC payload innovation, but also to drive meaningful breakthroughs in small molecule immuno-oncology. This expanded partnership reflects our commitment to building sustainable, innovation-driven biotech alliances.' 'We are pleased to collaborate with 1STBIO, a company with strong capabilities in small molecule drug discovery and oncology,' said Yong-Zu Kim, CEO of LigaChemBio. 'Beyond this partnership, we will continue to pursue open innovation with biotech companies worldwide to deliver transformative therapies to patients.' ### About 1ST Biotherapeutics, Inc. 1ST Biotherapeutics is a science-driven biopharmaceutical company focused on the development of breakthrough therapies in immuno-oncology, neurodegenerative diseases, and rare diseases. Founded in 2016, the Company has developed a pipeline of investigational drugs aimed at addressing critical unmet medical needs. The Company is headquartered in Yongin, South Korea. For more information, visit About LigaChem Biosciences LigaChem Biosciences (LCB, KOSDAQ: 141080) is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology and ADC platform technology ConjuAll™. Since its foundation in 2006, LCB has focused on the research and development of antibody-drug conjugates (ADCs), anticancer therapeutics based on proprietary platform technologies. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts, including statements regarding 1ST Biotherapeutics, Inc. ('1STBIO')'s research and development plans, the potential of its LRRK2-targeting candidates, its participation in the LITE program, and the expected impact of such participation on Parkinson's disease treatment development, are forward-looking statements. These statements reflect 1STBIO's current expectations and projections about future events and are subject to various risks, uncertainties, and assumptions. Actual results may differ materially and adversely from those expressed or implied in these statements due to a variety of factors. 1STBIO undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law. Contact 1ST Biotherapeutics, Inc. [email protected] Tel. +82 31 8023 5332 Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth Managing Partners [email protected] Tel. +49 40 88 16 59 64 / Tel. +49 30 23 63 27 68
